Differential Effects of Citrate Versus PPACK Anticoagulation on Measured Platelet Inhibition by Abciximab, Eptifibatide and Tirofiban

被引：0
作者：
Dean J. Kereiakes
Todd Lorenz
John J. Young
Gilbert Kukielka
Michele N. Mueller
Lisa Nanniazzi-Alaimo
David R. Phillips
机构：
[1] The Ohio Heart Health Center,The Carl and Edyth Lindner Center for Research and Education and
[2] Ohio State University,undefined
[3] COR Therapeutics,undefined
来源：
Journal of Thrombosis and Thrombolysis | 2001年 / 12卷
关键词：
platelet inhibition; anticoagulation; turbidometric aggregometry;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: High levels of glycoprotein (GP) IIb/IIIa receptor inhibition are required to prevent arterial thrombosis following percutaneous coronary intervention. Ex-vivo turbidometric platelet aggregation in citrate anticoagulated blood samples has been the primary method previously utilized to derive dose regimens for administering platelet GP IIb/IIIa inhibitors. Enhanced GP IIb/IIIa binding and inhibition of platelet aggregation for eptifibatide secondary to citrate induced reduction of ionized plasma calcium concentrations has been reported. Methods/Results: We evaluated the differential effects of citrate versus PPACK anticoagulation on turbidometric platelet inhibition in normal volunteers by eptifibatide, tirofiban or abciximab. The decrease in ionized calcium afforded by citrate was associated with enhanced in vitro platelet inhibition for all three GP IIb/IIIa inhibitors, including abciximab. The magnitude of citrate effect was greatest for eptifibatide. Both tirofiban and abciximab have similar citrate calcium chelation associated enhancement of measured platelet inhibition.
引用
收藏
页码：123 / 127
页数：4
相关论文
共 137 条
[1]  
Coller BS(1991)Monoclonal antibodies to platelet GPIIb/IIIa as antithrombotic agents Ann NY Acad Sci 614 193-213
[2]  
Scudder LE(1989)Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor: correlation with bleeding time, platelet aggregation and blockade of GPIIb/IIIa receptors Circulation 80 1766-1774
[3]  
Beer J(1998)Pharmcodynamic profile of short–term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade Circulation 97 1680-1688
[4]  
Gold HK(1994)Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high–risk coronary angioplasty Circulation 90 1757-1764
[5]  
Folts JD(1997)Clinical pharmacology of eptifibatide Am J Card 80 11B-20B
[6]  
Cavagnaro J(1996)Randomized, double–blind, placebo–controlled dose ranging study of tirofiban (MK–383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty J Am Coll Card 27 536-542
[7]  
Jordan R(2000)Role of extracellular ionized calcium in the in vitro assessment of GPIIb/IIIa antagonists J Thromb Thrombolysis 9 23-28
[8]  
Wagner C(1997)Scarborough RM. Effect of Ca Circulation 96 1488-1494
[9]  
Iuliucci J(1997) on GP IIb–IIIa interactions with integrilin: enhanced GP IIb IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate Lancet 349 1422-1428
[10]  
Knight D(1997)Randomised placebocontrolled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II Eur Heart J 18 3615-839
12345678910